Literature DB >> 11408944

Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct.

F Xu1, M F Prescott, P X Liu, Z H Chen, G Liau, E M Gordon, F L Hall.   

Abstract

Restenosis from neointimal proliferation is a frequent complication of intracoronary stenting and catheter-based revascularization procedures. Currently, there is no known therapeutic strategy that has been sufficiently effective to warrant its widespread use. In the present study, the anti-proliferative properties of a matrix (collagen)-targeted retroviral vector bearing a mutant cyclin G1 (DNT 41-249) construct was evaluated in vitro and in vivo. In controlled one-month efficacy studies, the intraluminal instillation of the mutant cyclin G1 vector significantly inhibited neointima lesion formation in balloon-injured rat arteries without neointimal growth, associated necrosis or intense inflammatory reaction. Taken together, these data extend the potential utility of the matrix-targeted mutant cyclin G1 retroviral vector for management of vascular restenosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408944     DOI: 10.3892/ijmm.8.1.19

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

1.  Development of viral vectors for use in cardiovascular gene therapy.

Authors:  Paul D Williams; Parisa Ranjzad; Salik J Kakar; Paul A Kingston
Journal:  Viruses       Date:  2010-01-27       Impact factor: 5.818

2.  Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Doris Quon; Andreh Saralou; William C Blackwelder; Frederick L Hall; Erlinda M Gordon
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

3.  Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Dorris Quon; William C Blackwelder; Erlinda M Gordon; Frederick L Hall
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454

4.  Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Authors:  Erlinda M Gordon; Joshua R Ravicz; Seiya Liu; Sant P Chawla; Frederick L Hall
Journal:  Mol Clin Oncol       Date:  2018-06-14

5.  A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.

Authors:  Sant P Chawla; Howard Bruckner; Michael A Morse; Nupur Assudani; Frederick L Hall; Erlinda M Gordon
Journal:  Mol Ther Oncolytics       Date:  2018-12-14       Impact factor: 7.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.